

Concepts	Learning Objectives	
Pruritus is the condition of sensory nerve stimulation producing an itching sensation due to signaling through histaminergic (histamine) and nonhistaminergic nerves (cytokines, proteases, etc). The histamine pathway involves binding to H1 and H4 histamine receptors on sensory neurons, PLC-mediated PIP2 cleavage, DAG activation of PKC and subsequent opening of TRPV1 and voltage-gated channels to trigger the action potential for itch signaling.	1 - Define the role of histamine in activation of the histaminergic nerve and subsequent molecular activities leading to action potential generation for pruritus. 2 - Distinguish pruritogens involved in nonhistaminergic and histaminergic nerve activation. What cytokines (Th2) are involved in nonhistaminergic nerve activation for pruritus signaling? How are PAR activated? What is the role of SP in pruritus? 3 - Define the contribution of MRGPR on mast cells and those compounds that bind to it. Review the pruritus pathway. 4 - Recognize exposure-related triggers of pruritus and system causes of itch. 5 - Define the mechanisms of type I and IV hypersensitivity and the activity of mast cells to promote pruritus. What are the major pruritogens for wheal and flare immediate responses?	8-9 10, 12, 14-15 16-17 18-20 22, 24-28

Concepts	Learning Objectives	
Urticaria (hives) is the condition involving the formation of a well-defined, nonpuritic edematous swelling of the subcutaneous tissues due to immune-mediated (type I hypersensitivity) and nonimmune (neuropeptides) mechanisms of mast cell activation. Pruritus can accompany urticaria but different mechanisms underlie each. Angioedema occurs when the mast cells degranulate in the deep dermis and subcutaneous tissue while urticaria occurs when mast cells degranulate in the upper dermis.	1 - Define the characteristics and causes of urticaria and angioedema. 2 - Mast cells are the primary mediators of urticaria and angioedema - recognize the mechanisms of activating mast cells involving type I-IV hypersensitivities. Mast cells can be activated in all. Mast cells are the primary mediator of type I hypersensitivity but can be active in all. 3 - Recognize how mast cells can be activated by nonimmune events such as direct binding of agents to mast cell receptors or drug actions and environment. 4 - Identify triggers of urticaria (and angioedema) as well as physical presentation of urticaria based upon the trigger. What clinical clues suggest a case of urticaria? What approaches and therapies are available?	34-36 37-40 41-42 42-48
When arthropods are disturbed or threatened or require food to continue growth and reproduction, often humans suffer bites, stings, infestations producing skin rashes involving pruritus and urticaria.	1 - Identify from the bite and coloration a millipede bite from other arthropod bites. Differentiate among sting lesions of the southern US caterpillars. 2 - Differentiate between the bites of mosquitoes, bedbugs, triatomine bugs, fleas, and lice based upon location and presentation of patient. Distinguish the presentation of scabies infestation from other arthropods. 3 - Differentiate brown recluse, black widow, tick, chiggers, and scorpion bites based on presentation, geography, environmental considerations, and symptoms. Contrast with the specific lesions caused by fire ant stings/bites.	51-58 60-66, 69, 72 66, 70-71, 73-76

L01 Histamine = acute itch

- released by mast cells, binds **H1 & H4**

on histaminergic nerves (**Gg**)

∴ PLC mediated **PIP2** cleavage

& **DAG** activates **PKC**

to **OPEN TRPV1** (both histamine & non)

& voltage-gated channels

→ **ACTION POTENTIAL**

→ **Excited Histaminergic Neurons** release:

① **CGRP** (calcitonin gene related peptide)

② **SP** (substance P)

Nonhistaminergic Nerve Activation

= **CYTOKINES**

★ **IL-31** → increased **Th2** response

★ **IL-4 & IL-13** → signal **Th2** resp.

★ **TSLP** → secreted by keratinocytes to stimulate **Th2**

Type I Hypersensitivity: Atopic Dermatitis

① uptake of allergen by DC

② **Th2** expansion

③ production **IgE** via **IL-4**

④ release mediators of inflammation upon **RE-exposure**

⑤ **Mast Cell** stimulation → immediately respond

TIL31 = Trecerity

Type IV Hypersensitivity: Allergic Contact Derm

- contact allergens form haptens,

★ effector memory T-cells (**Th1**) are generated & traffic to skin (takes 2 wks)

→ upon **re-exposure**:

- haptenated proteins on **MHC I & II**

- **CD8+ T-cells** produce lesions

via apoptosis + **MØ**

★ **Fas** expression on keratinocytes

= **BLISTERS**

- **CD4+ T-cells** ↑ **TNFα** & **IFN-γ**

= inflammation & itching

activate mast cell to potentiate itching

★ **Th1** → **TNFα** → itching

IMMEDIATE RESPONSE:

★ **wheal**: SP binds to **NK1** receptor

★ **flare**: **CGRP** (surrounding redness)

Concepts

Learning Objectives

Urticaria (hives) is the condition involving the formation of a well-defined, nonpuritic edematous swelling of the subcutaneous tissues due to immune-mediated (type I hypersensitivity) and nonimmune (neuropeptides) mechanisms of mast cell activation. Pruritus can accompany urticaria but different mechanisms underlie each. Angioedema occurs when the mast cells degranulate in the deep dermis and subcutaneous tissue while urticaria occurs when mast cells degranulate in the upper dermis.	1 - Define the characteristics and causes of urticaria and angioedema. 2 - Mast cells are the primary mediators of urticaria and angioedema - recognize the mechanisms of activating mast cells involving type I-IV hypersensitivities. Mast cells can be activated in all. Mast cells are the primary mediator of type I hypersensitivity but can be active in all. 3 - Recognize how mast cells can be activated by nonimmune events such as direct binding of agents to mast cell receptors or drug actions and environment. 4 - Identify triggers of urticaria (and angioedema) as well as physical presentation of urticaria based upon the trigger. What clinical clues suggest a case of urticaria? What approaches and therapies are available?	34-36 37-40 41-42 42-48
When arthropods are disturbed or threatened or require food to continue growth and reproduction, often humans suffer bites, stings, infestations producing skin rashes involving pruritus and urticaria.	1 - Identify from the bite and coloration a millipede bite from other arthropod bites. Differentiate among sting lesions of the southern US caterpillars. 2 - Differentiate between the bites of mosquitoes, bedbugs, triatomine bugs, fleas, and lice based upon location and presentation of patient. Distinguish the presentation of scabies infestation from other arthropods. 3 - Differentiate brown recluse, black widow, tick, chiggers, and scorpion bites based on presentation, geography, environmental considerations, and symptoms. Contrast with the specific lesions caused by fire ant stings/bites.	51-58 60-66, 69, 72 66, 70-71, 73-76

→ **urticaria** = degranulate in upper dermis

→ **angioedema** = degranulate in deep dermis & subQ

Type I Hypersensitivity:

= allergen reexposure binds to **IgE** triggering mast cell activation (**FcεR**)

Ex: food & drug allergies, bee stings, latex

Type II Hypersensitivity: AUTOIMMUNE → **HLA-DQ4**

= mast cell & basophil **FcγR** bind **IgG** autoantibody (self antigen binds mast cell) insoluble antigen

Type III Hypersensitivity:

= chronic Ag → **CIC** that bind **FcR** (soluble antigen)

ex: SLE, Hep B, longterm Ab

Type IV Hypersensitivity:

= upon reexposure, activated memory T-cells produce cytokines (**TNFα**)

★ **COLD & HEAT** can activate mast cells = **Nonimmunogenic**

★ pts w/ hx urticaria/angioedema → **EpiPen!**

L02 BITES & STINGS

★ Millipedes:


toxin = **benzoquinones**

→ cause skin to turn black for months

★ **Pur Caterpillar** oak & elm

toxin → **grid lesions**

= HA / Fever / Nausea, **Seizures**



★ Caterpillar stings:

Tx: **scotch tape**

★ Bedbugs: bite to feed on blood
- zigzag / linear pattern

★ Triatomine Bug: transmits T. cruzi
painless bite → papule
& Chagoma if parasite enters eye



★ Scabies: direct contact
Night itching
webs of fingers/toes
white linear curved lines on skin = tunneling

★ Brown Recluse
toxin: hemolytic enzymes → tissue destruction & necrosis



★ Black widow

TWO puncture wounds

TOXIN: neurotoxin (α-latrotoxin) → excessive neurotransmitter release
Sx: muscle spasms, CP, LBP, HTN, sweating, N/V, SOB



Difference between bug bites

	linear / zig-zag		
			
	Bed bug bites	Flea bites	Mosquito bites
LOCATION	Usually abdomen or arms (upper body)	Usually ankles or feet (lower body)	Can be anywhere
SIZE	Multiple big bites	Many small bites	Fewer big bites
PATTERN	Grouped together in a zig-zag or line	Grouped together, may form a pattern	No pattern

L03/04 Pharm of ID - Derm

CELLULITIS

★ outpatient:

TOX ★★
- purulent: CA-MRSA → TMP/SMX, ^{Ø GUPD} doxycycline, clindamycin, & linezolid ★
- nonpurulent: β-hemolytic strep → cephalexin or amoxicillin (β-lactams)
systemic: β-lactam + [TMP/SMX or tetracycline] OR linezolid OR clindamycin

★ inpatient: MRSA → IV antibiotics

DIABETIC FOOT → MC staph/strep, gram ⊖ bacilli anaerobes, or MRSA

mild/mod → target gram ⊕ cocci

TOX ★★ severe infx → broad spectrum empiric therapy ★

Pseudomonas RF → soaking feet, failed nonpseudo therapy, clinically severe infx ★

vanc + piptaz or vanc + carbapenem

what drug do you give?

TOX ★★ surgical prophylaxis → Cefazolin ★★

ACNE

★ comedonal: NON-inflammatory

TOX ★★
1x: topical tretinoin
MOA: vitamin A derivative ★
SE: burning

★ MILD papulopustular:

Benzoyl peroxide ± topical AB AND topical retinoid
OR

Benzoyl peroxide AND topical AB (clindamycin)

★ MODERATE papulopustular:

topical retinoid AND oral AB AND topical benzoyl peroxide

→ tetracyclines

★ SEVERE acne

(TQ)

isotretinoin (accutane)

★ HIGH RISK BIRTH DEFECTS → pledge program / pregnancy test every refill

MOA ★ reduces gland size & sebum production

LIDOCAINE

(TQ)

MOA: block Na⁺ channels

SE: arrhythmia when you apply to large area (legs)

CORTICOSTEROIDS

thin skin = more absorption ∴ go w/ LOW potency (face) ★

(TQ)

low: hydrocortisone

med: triamcinolone

high: clobetasol

→ SE: can cause skin atrophy

TACROLIMUS

= calcineurin inhibitor

★ alternative for topical corticosteroids @ sites w/ greatest risk of ^{corticosteroid induced} atrophy ★

★ AVOID atrophy!

STEVEN JOHNSONS SYNDROME

(TQ)

Sulfa drugs

Oral hypoglycemics

Anticonvulsants / antibiotics

Phenytoin / Penicillin

NSAIDs

AB: penicillins / sulfa

Phenytoin / carbamazepine / lamotrigine / valproic acid
allopurinol

DRUG INDUCED LUPUS

→ anti-histone antibodies ★ ★ ★

Sulfa

Hydralazine

Isoniazid

Procainamide

Etanercept

PHOTOSENSITIVITY

(TQ) ?

Tetracyclines

Sulfa

Fluoroquinolones

Amiodorone

5-FU

L05 Skin Ulcers

BY THE END OF THIS LECTURE, YOU SHOULD BE ABLE TO:

- Classify the stages of pressure injury.
- Discriminate between arterial ulcers and venous ulcers. Recognize neuropathic ulcers.
- Assess treatments for each of the above ulcer types.

YOU CANNOT REVERSE STAGE A PRESSURE ULCER!!

EXAMPLE: A STAGE 3 ULCER CAN IMPROVE, BUT CANNOT BECOME A STAGE 2. IT IS A HEALING STAGE 3 ULCER.

PRESSURE ULCERS:



STAGE 1: nonblanchable erythema, $\emptyset$ open draining wounds
tx: remove pressure + skin protectant

STAGE 2: partial thickness loss of skin w/ exposed dermis
may px as blister
tx: remove pressure + skin protectant

STAGE 3: full thickness loss of skin w/ visible fat in the ulcer & granulation tissue + epibole
may have slough or eschar
tx: offload, moist tx, drainage

STAGE 4: full thickness & tissue loss w/ exposed / palpable fascia, muscle, tendon, cartilage, or bone
tx: assess for bone infx, debride, skin graft

UNSTAGEABLE eschar / necrotic tissue covering unable to assess depth



DEEP TISSUE INJURY intact or non-intact skin w/ nonblanchable deep red/purple discoloration
may px blood filled blister

Deep Tissue Injury

Bruising may be the first sign of deep injury. May take days or weeks to fully reveal the extent of the tissue necrosis. Education of resident/family/caregivers is critically important.



Evaluation & Treatment:

1. remove pressure *
2. MOIST wound healing *
3. debridement
4. wound vac

+ Nutrition

ARTERIAL ULCERS arterial occlusion $\rightarrow$ claudication / rest pain

"cookie-cutter" punched out lesions

PAINFUL, usually DRY
ankles & feet

dx: ABI

> 1.0 = Normal

< 0.8 = referral for revascularization

tx: revasc (if needed) & moist wound healing

$\rightarrow$ paint w/ betadine until surgery

VENOUS ULCERS d/t venous insuff $\rightarrow$ high pressure $\rightarrow$ fluid leaks

between leg & ankle

irregular, shallow, painful, **EXUDATE**

dx: duplex ultrasound + ABI

tx: compress, elevate, pump // vein clinic for ablation $\rightarrow$ decreases chance of ulcer recurrence *

& took over neuropathic ulcers...

TO
pt comes in w/ stage 3 ulcer & it gets better during their stay $\rightarrow$ STILL STAGE 3!

systolic

Right ABI = $\frac{\text{Highest pressure in Right foot}}{\text{Highest pressure in BOTH arms}}$

Left ABI = $\frac{\text{Highest pressure in Left foot}}{\text{Highest pressure in BOTH arms}}$

LOW Burn

F(x) of skin:

→ Epidermis: protection / fluid balance / neurosensory

→ Dermis: protection (elastic & durable), THERMOREG. ✱

- Understand the consequences of burn induced skin barrier loss ✓
- Identify burns by degree ✓
- Have an understanding of burn treatment based on severity ✓
- Recognize signs of infection in a burn patient ✓

Burn severity - decides tx plan

✱ Burn depth: depends on degree of heat & depth penet.

- Scalding heat travels FASTER

- 1st factor dictating wound mgmt

✱ wound conversion via infx, pressure, poor nutrition

(TQ) ✱ wound infection:

↑ edema

↑ sloughing

softening of subeschar

✱ don't rely on WBC

(TQ) ✱ rule of 9's

calculate

H/N = 9%

Chest / upper back = 9% each


arms = 9% each

genitals = 1%

legs = 18% each

Complications of burns-loss of skin barrier

- -increased heat loss (hypothermia)
- -increased infection risk
- -wound dessication
- -increased evaporative water loss → fluids!
- -loss of sensation or hyperalgesia
- -loss of skin elasticity



Superficial (first degree) = epidermis ONLY, no barrier function alteration

tx: aloe, moisturizers, cool water Ice ✱ ✱

Partial thickness (second degree) = epidermis & part of inner dermis (blisters)

tx: elevate, sulfadiazine, moisturize

Full Thickness (third degree) = both layers of skin

tx: debride, graft, circumferential = escharotomy
refer to burn center

Subepidermal (4th degree) = both layers & subdermal / tendon & bone involvement

burn center

debride, graft, maybe amputation

LO7 Acute Burn Injuries

Initial triage:

- ① remove all clothing
- ② stop burning process (no ice)
- ③ prevent hypothermia*

Airway management

- inhalation injury

- inhalation thermal injury → hoarse voice*

TO

- CO poisoning → hypoxia/anoxia (found down) → give 100% O₂; ∇ HBOC for burn patients

- inhaled chemicals/irritants → px later

- edema d/t $\uparrow$ capillary permeability + inflammation

* $>20\%$ = systemic edema → AIRWAY PROBLEM

* escharotomy for ventilation to $\downarrow$ pressure

TBSA

* palmar method: pts palm = 1% TBSA

* indication for fluid resuscitation:

[$>20\%$ TBSA
 $>65y/o$ or $<2y/o$ any size] → GIVE LR, large bore IV, ASAP

FORMULAS

prehospital: * Disaster = [$\% \text{ TBSA} \times 10 \text{ mL}$] + 100 mL for every 10 kg $>80 \text{ kg}$

TBSA-based:

* Parkland = $4 \text{ mL} \times \text{kg} \times \% \text{ TBSA}$

* Brooke = $2 \text{ mL} \times \text{kg} \times \% \text{ TBSA}$

* Pediatric = $3 \text{ mL} \times \text{kg} \times \% \text{ TBSA}$

→ adjust based on UOP

too much UOP = $\downarrow 10\%$

too little UOP = $\uparrow 10\%$

adult UOP = 30-50 mL/hr
 peds UOP = 0.5-1 mL/kg/hr

TO *

BURNS

* Tar = thermal injury

cool tar, remove w/ petroleum based ointment

* Scald = time/temp. of liquid

100° = instant burn

* Grease (350-375°)

always full thickness, velchar

* Non-accidental scalds

o splash, clear demarc

* Flash/Flame

→ Flash: 0 full thickness

→ Flame: deep, eschar immediate

TO

* Chemical burns

* pH >7 → saponification, soapy skin

* pH <7 → coag. necrosis, tans skin

* Tx: flush continuously 20 min (unless powder)



→ trumps everything
 confused, awake
 → CO poisoning

Initial fluid management

* Initial fluid formula based on age alone

- * $<5 \text{ y/o}$ 125 mL/hr of LR
- * $6-14 \text{ y/o}$ 250 mL/hr of LR
- * $>15 \text{ y/o}$ 500 mL/hr of LR

* Before you get to ER(?)

Treatment

Sheet Autograft

Advantages:

- more durable than mesh grafts
- more cosmetic
- contracts less than mesh grafts

Disadvantages:

- Bacteria/fluid may collect under the graft causing graft loss.

LO8 Complex wound/skin conditions

★ Congenital Nevomelanocytic Nevus

potentially malignant

large: > 2% TBSA or > 20cm

tx: surgery after 6mos age

★ Capillary malformation

= port wine stain

tx: V-beam laser

★ Hidradenitis Suppurativa

relapsing inflammatory dz of apocrine sweat glands

ABSCESSES @ axillae & inguinal

tx: EXCISION & grafting = best outcome

★ ★
★ (TO) ↓

★ Purpura fulminans

purpuric skin lesion, fever, DIC

tx: neonatal: plasma + anticoag ★

- idiopathic/infx: Ab + supportive care

★ Staph scalded skin syndrome

hx infection, dx of bacterial sepsis

exfoliative toxin

tx: Abx, Hydration, wound care

★ Erythema multiforme

SOAPs:

Sulfa

Oral hypoglycemic

anti convulsants /
antibiotics

phenytoin / Penicillin

NSAIDs

Treatment

- Wound care
- Enteral feeds due to oral lesions
- Foley catheter due to penile ulcerations
- Eye lubricants for protection
- Anxiety and pain control

	Erythema Multiforme (EM) Minor/major	Stevens-Johnson Syndrome (SJS)	Toxic epidermal necrolysis (TENS)
History	Fever /malaise/cough Joint pain	Fever/malaise	Fever/malaise
Mucosal involvement	Minor: no involvement Major: one or more	Yes	Yes
Skin slough	Minor: localized eruption. Target shaped lesions Major: lesions slough < 10%	< 10% TBSA	> 30% TBSA
Duration	1-4 weeks. Reoccurrence expected	1-6 weeks	1-6 weeks
Mortality	> 5%	0-40%	25-80%
Cause	Most cases bacterial/viral 55% cases caused by HSV	Rxn to foreign agent	Drugs implicated 77-94% of cases